• Publications
  • Influence
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
TLDR
Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
TLDR
In patients with advanced RCC, CCI-779 showed antitumor activity and encouraging survival and was generally well tolerated over the three dose levels tested.
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
TLDR
Ipilimumab has activity in some patients with advanced melanoma and brain metastases, particularly when metastases are small and asymptomatic, and the drug has no unexpected toxic effects in this population.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
TLDR
Frentinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patientsWith germline MET mutations, the presence of a germlineMET mutation was highly predictive of a response.
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
TLDR
This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
TLDR
In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-free survival compared with everolimus, and future trials of novel agents should account for heterogeneity in disease outcomes based on genetic, histological, and prognostic factors.
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
TLDR
The combination of vemurafenib and cobimetinib was safe and tolerable when administered at the respective maximum tolerated doses, and has promising antitumour activity.
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
TLDR
One course of high-dose bolus IL-2, though feasible, did not produce the ambitious clinically meaningful benefit anticipated when administered postoperatively to patients with resected high-risk RCC.
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable
TLDR
The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilitationab alone, indicating that the combination has greater antitumor activity without additional safety concerns versus ipILimumab.
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
TLDR
Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer.
...
1
2
3
4
5
...